Kagase Ai, Yamamoto Masanori, Shimura Tetsuro, Kodama Atsuko, Kano Seiji, Koyama Yutaka, Tada Norio, Naganuma Toru, Araki Motoharu, Yamanaka Futoshi, Shirai Shinichi, Watanabe Yusuke, Hayashida Kentaro
Department of cardiology, Toyohashi Heart Center, Toyohashi, Japan.
Department of cardiology, Nagoya Heart Center, Nagoya, Japan.
Catheter Cardiovasc Interv. 2018 Aug 1;92(2):E125-E134. doi: 10.1002/ccd.27483. Epub 2018 Jan 11.
Hyponatremia is associated with the increased risk of early and late mortality in patients with cardiac disease. This study aimed to assess the prognostic value of hyponatremia in patients who had undergone transcatheter aortic valve replacement (TAVR).
We investigated 1,215 consecutive patients (mean age: 84.4 ± 5.0 years) who underwent TAVR using data from the Optimized CathEter vAlvular iNtervention (OCEAN)-TAVR Japanese multicenter registry. Hyponatremia was defined as a serum sodium value less than 135 mEq/L. The baseline characteristics, procedural outcomes, all-cause, cardiovascular, and non-cardiovascular mortality were compared between patients with hyponatremia (n = 106, 8.7%) and without hyponatremia (n = 1,109, 91.3%). A propensity-matching analysis was used to adjust for the non-uniform patient characteristics.
Differences in the baseline characteristics were observed between the two groups regarding the prevalence of pulmonary disease (37.7% vs. 28.9%, P = 0.04) and the performance of non-elective TAVR (10.4% vs. 4.2%, P = 0.01), although these were minimized in the matched model. The 30-day mortality rates differed between the two groups (7.6% vs. 1.4%, P < 0.001). During a mean follow-up of 330 days, the all-cause and cardiovascular mid-term mortality were higher in the hyponatremia group than in the non-hyponatremia group (log-rank test: P = 0.0047, and P < 0.001, respectively). The three findings above were not attenuated in the propensity-matched model (P < 0.001, P = 0.0044, and P = 0.014, respectively). In contrast, there was no difference in non-cardiovascular mortality between the two groups in both the overall and matched model (P = 0.40 and P = 0.13, respectively).
Pre-procedural hyponatremia may be a useful marker for predicting early and mid-term clinical outcomes after TAVR.
低钠血症与心脏病患者早期和晚期死亡风险增加相关。本研究旨在评估低钠血症在接受经导管主动脉瓣置换术(TAVR)患者中的预后价值。
我们利用优化导管瓣膜介入(OCEAN)-TAVR日本多中心注册研究的数据,调查了1215例连续接受TAVR的患者(平均年龄:84.4±5.0岁)。低钠血症定义为血清钠值低于135 mEq/L。比较低钠血症患者(n = 106,8.7%)和无低钠血症患者(n = 1109,91.3%)的基线特征、手术结果、全因、心血管和非心血管死亡率。采用倾向匹配分析来调整患者特征的不均衡性。
两组在肺部疾病患病率(37.7%对28.9%,P = 0.04)和非择期TAVR的实施情况(10.4%对4.2%,P = 0.01)方面观察到基线特征存在差异,尽管在匹配模型中这些差异被最小化。两组的30天死亡率不同(7.6%对1.4%,P < 0.001)。在平均330天的随访期间,低钠血症组的全因和心血管中期死亡率高于非低钠血症组(对数秩检验:P = 0.0047和P < 0.001)。上述三项结果在倾向匹配模型中未减弱(分别为P < 0.001、P = 0.0044和P = 0.014)。相比之下,在总体模型和匹配模型中,两组的非心血管死亡率均无差异(分别为P = 0.40和P = 0.13)。
术前低钠血症可能是预测TAVR术后早期和中期临床结果的有用指标。